The Rhematoid Arthritis Market

Published : October 2010
No. of Pages : 125

Price:

Report Summary

Rheumatoid arthritis, a systemic disease characterized by inflammation of the membrane lining the joint, is one of the most common forms of arthritis. Up to 50 percent of all rheumatoid arthritis patients enter early retirement within five years of diagnosis, which means that the indirect costs associated with this disease can be very high. While the prevalence of rheumatoid arthritis has decreased in recent years, partly due to stricter diagnosing criteria as well as other unknown factors, the higher uptake of rheumatoid arthritis therapies continues to represent a major commercial opportunity for pharmaceutical companies involved in the research and development of novel therapies for the disease.

The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis is an analytically-based overview of the current state of the global market for rheumatoid arthritis therapies, with a focus on the specific class of drugs, known as the biological response modifiers (BRMs). Biological response modifiers have revolutionized the treatment of rheumatoid arthritis, although their high cost (of up to $16,000 per patient per annum), has been a major point of contention for both Medicare reimbursement as well as private insurers. Consequently, an increasing amount of attention has been devoted to research into their cost-effectiveness as compared to other therapies, as well as one another. This report compares and contrasts the key rheumatoid arthritis therapies on the market as well as in research and development.

The report also offers a comprehensive overview of therapeutics currently in clinical development, with a view to assessing their impact on the future performance of leading rheumatoid arthritis drugs. As a class, biological response modifiers will, without a doubt, continue to make a major impact on the rheumatoid arthritis market. However, the leading drugs within this class are facing challenging times ahead, with a number of new products already reaching registration phases, led by Centocor/Schering-Plough’s Simponi and Celltech/UCB’s Cimzia.

The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis provides sales figures for major rheumatoid therapies, dating back to 2003, as well as sales forecasts through 2013. Apart from patent expirations facing current biological response modifiers and new product launches, which will increase price competition, there are a few other factors expected to slow down growth in this market during the next five years. For example, recent developments in the United Kingdom (UK) suggest that cost-containment may limit the use of expensive biologics if the first course of treatment fails. Similarly, a more intense scrutiny of adverse drug reactions may also limit this class’s reach in the market, although such issues will continue to be the driving force behind research into safer and more convenient methods of administration.

Table Of Contents

1 EXECUTIVE SUMMARY
1.1 Scope and Methodology
1.2 Rheumatoid Arthritis: Disease Background, Impact and Treatment
1.3 Market Growth
1.4 Research and Development (R&D) Trends

2 RHEUMATOID ARTHRITIS: SCIENTIFIC BACKGROUND
2.1 Disease Overview
2.2 Etiology of Rheumatoid Arthritis
2.2.1 Genetic Factors
2.3 The Immune Response
2.3.1 Cytokines
2.3.2 Helper T-Cells and RA
2.3.3 Leukocytes
2.4 Symptoms
2.5 Diagnosis
2.5.1 Diagnostic Criteria
2.6 Risk Factors
2.6.1 Genetic Factors
2.6.2 Stress Hormones
2.6.3 Gender
2.6.4 Age
2.6.5 Family History
2.6.6 Ethnic Background
2.7 Key Clinical Trial Endpoints
2.7.1 American College of Rheumatology (ACR) Disease Activity Measures
2.7.2 EULAR (European League Against Rheumatism) Response Criteria
2.7.3 Erythrocyte Sedimentation Rate (ESR)
2.7.4 C-Reactive Proteins (CRP)
2.8 Prognosis

3 THE FINANCIAL AND DEMOGRAPHIC IMPACT OF RHEUMATOID ARTHRITIS
3.1 The Prevalence and Incidence of Rheumatoid Arthritis
3.1.1 Worldwide
3.1.2 US
3.2 The Financial Impact of Rheumatoid Arthritis

4 CURRENT TREATMENT OPTIONS FOR RHEUMATOID ARTHRITIS
4.1 NSAIDs
4.2 Corticosteroids
4.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
4.4 Biological Response Modifiers (BRMs)
4.4.1 Key Biological Response Modifiers
4.5 Surgical Treatments
4.5.1 Osteotomy
4.5.2 Synovectomy
4.5.3 Arthroscopic Surgery
4.5.4 Arthroplasty
4.5.5 Arthrodesis
4.6 Other Existing Treatments

5 ISSUES AND TRENDS IMPACTING THE GLOBAL MARKET FOR RA THERAPIES
5.1 Biological Response Modifiers as a Continued Market Force
5.2 DMARDs vs BRMs
5.3 The High Cost of RA Biologics
5.4 Medicare Reform in the US: Impact on RA Market
5.5 RA Therapies and Global Reimbursement Issues

6 THE GLOBAL MARKET FOR RA THERAPIES
6.1 Commercial Market Size
6.1.1 US Revenues
6.1.2 Non-US Revenues
6.2 Key Products Driving Growth
6.2.1 Enbrel: Market Position and Revenues
6.2.2 Remicade: Market Position and Revenues
6.2.3 Humira: Market Position and Revenues
6.2.4 Orencia: Market Position and Revenues
6.2.5 Rituxan: Market Position and Revenues
6.2.6 Kineret: Market Position and Revenues
6.3 Market Share
6.3.1 By Product
6.3.2 By Country/Region

7 THE R&D PIPELINE FOR RA THERAPIES
7.1 Unmet Need
7.2 R&D Trends in RA Therapy
7.2.1 Products Nearing Commercialization
7.2.2 Future Directions
7.3 R&D Trends in RA Therapy
7.3.1 Cimzia (CDP-870)
7.3.2 Actemra
7.3.3 Simponi
7.4 Selected Phase III Products in Development
7.4.1 Arzerra (HuMax-CD 20)
7.4.2 CP-690550
7.4.3 Ocrelizumab (R1594)
7.5 Selected Phase II Products in Development
7.5.1 Eculizumab
7.5.2 INCB018424
7.5.3 ALD-518
7.5.4 P38 MAP Kinase Inhibitor
7.5.5 BMS 561392
7.5.6 Lymphostat-B
7.5.7 VX 702

8 THE FINANCIAL OUTLOOK FOR THE RA THERAPY MARKET
8.1 Financial Forecasts for Key Products
8.1.1 Enbrel
8.1.2 Remicade
8.1.3 Humira
8.1.4 Orencia
8.1.5 Rituxan
8.2 Overall Financial Forecast for RA Market 2009-2013

GRAPHS

Graph 3.1 Prevalence of RA in Various Countries
Graph 6.1 Global Sales of Leading RA Therapies 2003-2008, by product ($ mn)
Graph 6.2 US Sales of Leading RA Therapies 2003-2008, by product ($ mn)
Graph 6.3 Non-US Sales of Leading RA Therapies 2003-2008, by product ($ mn)
Graph 6.4 Enbrel Market Share, by Country/Region 2008
Graph 6.5 Remicade Market Share, by Country/Region 2008
Graph 6.6 Humira Market Share, by Country/Region 2008
Graph 6.7 Orencia Market Share, by Country/Region 2008
Graph 6.8 Global Market Share of Leading RA Therapies by Product, 2008
Graph 6.9 US Market Share of Leading RA Therapies by Product, 2008
Graph 6.10 Non-US Market Share of Leading RA Therapies by Product, 2008
Graph 6.11 RA Therapy Market Share, by Country/Region 2008
Graph 8.1 Sales Forecast for Enbrel 2009-2013
Graph 8.2 Sales Forecast for Remicade 2009-2013
Graph 8.3 Sales Forecast for Humira 2009-2013
Graph 8.4 Sales Forecast for Orencia 2009-2013
Graph 8.5 Sales Forecast for Rituxan 2009-2013

List of FIGURES

Figure 4.1 Treatment Options for Rheumatoid Arthritis

List of TABLES

Table 4.1 Percent of Patients with ACR Responses in Studies 1 and 3
Table 5.1 Approved DMARDs for Rheumatoid Arthritis
Table 5.2 Profiles of the Leading DMARDs and BRMs (2008)
Table 6.1 Global Sales of Key BRMs for Rheumatoid Arthritis, 2003-2008 ($ million)
Table 6.2 US Sales of Leading RA Therapies 2003-2008 ($ mn)
Table 6.3 Non-US Sales of Leading RA Therapies 2003-2008 ($ mn)
Table 6.4 Global Sales of Enbrel, US & Canada, Rest of World 2003-2008 ($ mn)
Table 6.5 Sales of Remicade 2003-2008, US, Japan, Europe + Rest of World ($ mn)
Table 6.6 Global Sales of Humira, US, Rest of World 2003-2008 ($ mn)
Table 6.7 Global Sales of Orencia, US, Rest of World 2006-2008 ($ mn)
Table 7.1 Rheumatoid Arthritis Drugs in Late-Stage Development
Table 7.2 Rheumatoid Arthritis Drugs in Early-Stage Development
Table 8.1 Patent Expirations for Key RA Products
Table 8.2 Financial Growth Forecast of the Biologics in the RA Market 2009-2013 ($ mn)

The Rhematoid Arthritis Market

Published By: Arrowhead Publishers

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: